EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

Drug Exposure and Treatment Outcomes in Patients With Multidrug-Resistant Tuberculosis and Diabetes Mellitus: A Multicenter Prospective Cohort Study From China

Yue Zhu, Lina Davies Forsman, Cheng Chen, Haoyue Zhang, Ge Shao, Sainan Wang, Shanshan Wang, Haiyan Xiong, Judith Bruchfeld, Weibing Wang, Limei Zhu, Jan-Willem Alffenaar und 1 weitere

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciae329 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Yue Zhu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Tuberculosis, Multidrug-Resistant, Antitubercular Agents, Microbial Sensitivity Tests, Mycobacterium tuberculosis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Shanghai 3-year (2023-2025) action plan to strengthen the public health system, National Natural Science Foundation of China, Fudan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The management of multidrug-resistant tuberculosis (MDR-TB) remains challenging. Treatment outcome is influenced by multiple factors; the specific roles of diabetes and glycemic control remain uncertain. This study aims to assess the impact of glycemic control on drug exposure, to investigate the association between drug exposure and treatment outcomes, and to identify clinically significant thresholds predictive of treatment outcome, among patients with diabetes.

Methods

This multicenter prospective cohort study involved patients with confirmed MDR-TB and diabetes. Drug exposure level was estimated by noncompartmental analysis. The minimum inhibitory concentrations (MICs) were determined for the individual Mycobacterium tuberculosis isolates. The influence of poor glycemic control (glycated hemoglobin ≥7%) on drug exposure and the associations between drug exposure and treatment outcome were evaluated by univariate and multivariate analysis. Classification and regression tree analysis was used to identify the drug exposure/susceptibility thresholds.

Results

Among the 131 diabetic participants, 43 (32.8%) exhibited poor glycemic control. Poor glycemic control was independently associated with decreased exposure to moxifloxacin, linezolid, bedaquiline, and cycloserine, but not clofazimine. Additionally, a higher ratio of drug exposure to susceptibility was found to be associated with a favorable MDR-TB treatment outcome. Thresholds predictive of 6-month culture conversion and favorable outcome were bedaquiline area under the concentration–time curve (AUC)/MIC ≥245 and moxifloxacin AUC/MIC ≥67, demonstrating predictive accuracy in patients, regardless of their glycemic control status.

Conclusions

Glycemic control and optimal TB drug exposure are associated with improved treatment outcomes. This dual management strategy should be further validated in randomized controlled trials of patients with MDR-TB and diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tuberculosis, Multidrug-ResistantAntitubercular AgentsMicrobial Sensitivity TestsMycobacterium tuberculosisHumansMaleFemaleProspective StudiesMiddle AgedChinaAdultTreatment OutcomeDiabetes MellitusMoxifloxacinLinezolidCycloserineDiarylquinolinesAgedClofazimineGlycated Hemoglobin

Stichwörter der Autor:innen

drug exposureglycemic controlmultidrug-resistant tuberculosistreatment responsetype 2 diabetes mellitus

Substanzen

Antitubercular AgentsMoxifloxacinbedaquilineLinezolidCycloserineDiarylquinolinesClofazimineGlycated Hemoglobin

Autor:innen und Institutionen

  • Department of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety, Fudan University, Shanghai, China.
  • Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Medicine, Division of Infectious Diseases, Karolinska Institutet, Solna, Stockholm, Sweden.
  • Department of Chronic Communicable Disease, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
  • Faculty of Medicine and Health, School of Pharmacy, University of Sydney, Sydney, Australia.
  • Department of Clinical Pharmacology, Westmead Hospital, Sydney, Australia.

Förderung

  • Shanghai 3-year (2023-2025) action plan to strengthen the public health system
  • National Natural Science Foundation of China
  • Fudan University
  • Shanghai Health Committee

Zitieren

APA

Zhu, Y., Forsman, L. D., Chen, C., Zhang, H., Shao, G., Wang, S., Wang, S., Xiong, H., Bruchfeld, J., Wang, W., Zhu, L., Alffenaar, J. W., & Hu, Y. (2024). Drug Exposure and Treatment Outcomes in Patients With Multidrug-Resistant Tuberculosis and Diabetes Mellitus: A Multicenter Prospective Cohort Study From China. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae329

Vancouver

Zhu Y, Forsman LD, Chen C, Zhang H, Shao G, Wang S, et al. Drug Exposure and Treatment Outcomes in Patients With Multidrug-Resistant Tuberculosis and Diabetes Mellitus: A Multicenter Prospective Cohort Study From China. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae329

BibTeX
@article{Zhu2024,
  author = {Zhu, Yue and Forsman, Lina Davies and Chen, Cheng and Zhang, Haoyue and Shao, Ge and Wang, Sainan and Wang, Shanshan and Xiong, Haiyan and Bruchfeld, Judith and Wang, Weibing and Zhu, Limei and Alffenaar, Jan-Willem and Hu, Yi},
  title = {Drug Exposure and Treatment Outcomes in Patients With Multidrug-Resistant Tuberculosis and Diabetes Mellitus: A Multicenter Prospective Cohort Study From China},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciae329}
}
Kostenlos starten →